Industry-Sponsored Symposium - Transitioning Treatment Through New Immunological Pathways in Inflammatory Bowel Disease
Sunday, October 25, 2020
William J. Sandborn, MD, FACG, Kim L. Isaacs, MD, PhD, FACG, Bruce E. Sands, MD, MS, FACG
6:15 pm – 7:45 pm (Eastern time), Sunday, October 25
This activity is supported by an educational grant from Genentech, Inc.
Drs. Sandborn, Isaacs, and Sands will summarize new evidence on investigational agents with unique mechanisms of action that are in late-stage development for the treatment of moderate-to-severe inflammatory bowel disease (IBD). They will evaluate the most recent clinical findings on the safety and efficacy of therapies that target immunological pathways. They will also assess therapeutic regimens for moderate-to-severe IBD for their ability to improve outcomes in patients who are tumor necrosis factor (TNF) inhibitor-naïve or have previously received TNF inhibitors.
Industry-sponsored satellite symposia provide additional educational opportunities for attendees. Open to all Virtual ACG 2020 registered attendees, these programs are independent of the ACG 2020 Annual Scientific Meeting and Postgraduate Course programs. The ACG is not the continuing medical education provider of these programs. To register, add the program to your schedule within the ACG 2020 virtual meeting platform.